The TWiV team reveals the repertoire of anti-viral antibodies in newborn humans, and a complement protein that binds the adenovirus capsid and prevents release of the viral DNA.
Vincent travels to Microbiotix, Inc, a biopharmaceutical company in Worcester, MA to speak with four members of the company about their discovery and development of small molecule drugs that target serious infectious diseases.
At the University of Zürich, Vincent speaks with virologists Cornel Fraeful, Urs Greber, and Silke Stertz about their careers and their work on AAV2, adenovirus entry, and influenza virus.
The TWiVome reveal the first eukaryotic genes in a bacteriophage of Wolbachia, and how DNA tumor virus oncogenes antagonize sensing of cytoplasmic DNA by the cell.
At the Glasgow Science Festival microTALKS, Vincent speaks with Ruth, Glen, and Esther about their research on viruses and Hodgkin lymphoma, adenovirus structure and entry into cells, and interactions between arthropod borne viruses and their hosts.
Vincent, Rich, and Kathy and their guests Clodagh and Ron recorded this episode at the 33rd annual meeting of the American Society for Virology at Colorado State University in Ft. Collins, Colorado.
This episode of TWiV was recorded before an audience at the Beth Israel Deaconess Medical Center, where Vincent and Alan spoke with Dan and Jeff about AIDS vaccines.
Vincent, Alan, and Kathy discuss how coagulation factor X binding to adenovirus activates the innate immune system, and a novel polyomavirus associated with brain tumors in raccoons.
Vincent, Alan, Matt and Kathy review isolation of a new coronavirus from two patients in the Middle East, and expansion of the enteric virome during simian AIDS.
Vincent and Rich meet up with Mark Challberg to talk about his scientific career studying viral DNA replication, and his transition to an NIH Program Officer.